Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > 4 years - changed 3 times ...
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(82)
•••
Comment by JimmyJon Jul 16, 2021 10:20am
139 Views
Post# 33558906

RE:RE:RE:4 years - changed 3 times ...

RE:RE:RE:4 years - changed 3 times ...
MrMugsy wrote:
JimmyJ wrote: I've been invested in ATE and following this board since early 2019.  Every comment taken with a grain of salt Ofc.   I don't know where you guys find the time to post so much though lol.  The longs I know typically don't check stocks on a daily basis as everyone here does seemingly with obsession.  Makes me wonder at times 



That's right Jimmy - grain of salt - until you really get to know a few characters here - then you let your guard down on the private messaging side.

You can wonder why we're here Jimmy but - there really aren't many of us to wonder about.  If you knew my story - trust me - not much that you don't already know about me.

If you think I'm getting paid then please assume I'm making millions ... with growing revenues.  I'd like to be seen as that guy.

: )


 

All good Mugsy, I don't think that tbh.  You have good intentions that is clearly evident in your posts.  My comments are not directed at you but more in general.  There's lots of good and bad energy around here lately.  Sometimes it's good to walkaway and check in from time to time. 

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities